Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks

At the Product Quality Research Institute (PQRI) Workshop held last January 14–15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of characterization, formulation development, manufacturing, and nonclinical safety evaluation of nanomaterial-containing drug products for human use. The workshop discussions identified areas where additional understanding of material attributes, absorption, biodistribution, cellular and tissue uptake, and disposition of nanosized particles would continue to inform their safe use in drug products. Analytical techniques and methods used for in vitro characterization and stability testing of formulations containing nanomaterials were discussed, along with their advantages and limitations. Areas where additional regulatory guidance and material characterization standards would help in the development and approval of nanomedicines were explored. Representatives from the US Food and Drug Administration (USFDA), Health Canada, and European Medicines Agency (EMA) presented information about the diversity of nanomaterials in approved and newly developed drug products. USFDA, Health Canada, and EMA regulators discussed the applicability of current regulatory policies in presentations and open discussion. Information contained in several of the recent EMA reflection papers was discussed in detail, along with their scope and intent to enhance scientific understanding about disposition, efficacy, and safety of nanomaterials introduced in vivo and regulatory requirements for testing and market authorization. Opportunities for interaction with regulatory agencies during the lifecycle of nanomedicines were also addressed at the meeting. This is a summary of the workshop presentations and discussions, including considerations for future regulatory guidance on drug products containing nanomaterials.

[1]  Matthew Howard,et al.  Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm , 2014, AAPS PharmSciTech.

[2]  C. Sayes The Relationships among Structure, Activity, and Toxicity of Engineered Nanoparticles , 2014 .

[3]  M. Walsh,et al.  Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[4]  Haibo Zhou,et al.  Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Rong-Kun Chang,et al.  Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. , 2013, Journal of pharmaceutical sciences.

[6]  Jan P Möschwitzer,et al.  Drug nanocrystals in the commercial pharmaceutical development process. , 2013, International journal of pharmaceutics.

[7]  R. Duncan,et al.  Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. , 2013, Nanomedicine.

[8]  Celia N. Cruz,et al.  CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products , 2013, The AAPS Journal.

[9]  Sokindra Kumar,et al.  Nanoparticles-mediated drug delivery approaches for cancer targeting: a review , 2013, Journal of drug targeting.

[10]  Marina A. Dobrovolskaia,et al.  Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[11]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[12]  Fang Wang,et al.  Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs , 2012, Pharmaceutical Research.

[13]  V. Bae-Jump,et al.  126 Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC) , 2012 .

[14]  Y. Bang,et al.  Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients , 2012, International journal of nanomedicine.

[15]  T. Ishida,et al.  Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. , 2012, International journal of pharmaceutics.

[16]  T. Andresen,et al.  Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts , 2012, Journal of Innate Immunity.

[17]  Vladimir Torchilin,et al.  Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.

[18]  W. Zamboni,et al.  Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents , 2012, Clinical pharmacology and therapeutics.

[19]  V. Bae-Jump,et al.  Abstract 2673: Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer , 2012 .

[20]  D. Kingston,et al.  Conformationally constrained and nanoparticle-targeted paclitaxels , 2012, Pure and applied chemistry. Chimie pure et appliquee.

[21]  H. Nasrallah,et al.  Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. , 2012, Reviews on recent clinical trials.

[22]  G. Van den Mooter,et al.  Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in‐vitro release from sugar beads , 2011, The Journal of pharmacy and pharmacology.

[23]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[24]  Suzanne M D'Addio,et al.  Controlling drug nanoparticle formation by rapid precipitation. , 2011, Advanced drug delivery reviews.

[25]  Elaine Merisko-Liversidge,et al.  Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.

[26]  S. Ramalingam,et al.  Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors , 2011, Journal of liposome research.

[27]  Rainer H Müller,et al.  State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  Jinming Gao,et al.  Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.

[29]  J. Kolitz,et al.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Kenneth A. Dawson,et al.  Nanobiotechnology: nanoparticle coronas take shape. , 2011, Nature nanotechnology.

[31]  M. Dobrovolskaia,et al.  In vitro analysis of nanoparticle uptake by macrophages using chemiluminescence. , 2011, Methods in molecular biology.

[32]  A. Gabizon,et al.  Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients , 2011, Cancer Chemotherapy and Pharmacology.

[33]  G. Kulkarni,et al.  Optimization of formulation and process variable of nanosuspension: An industrial perspective. , 2010, International journal of pharmaceutics.

[34]  Jouni Hirvonen,et al.  Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods , 2010, The Journal of pharmacy and pharmacology.

[35]  Ranjita Shegokar,et al.  Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.

[36]  Lawrence Tamarkin,et al.  Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.

[37]  S. Barni,et al.  Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel , 2010, Expert opinion on pharmacotherapy.

[38]  W. Zamboni,et al.  DDS製品開発の最前線 Formulation and physiological factors affecting the pharmacokinetics and pharmacodynamics of liposomal anticancer agents , 2010 .

[39]  S. Ramalingam,et al.  Pharmacokinetic Study of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies , 2009, Clinical pharmacology and therapeutics.

[40]  Nakissa Sadrieh,et al.  Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. , 2009, Advanced drug delivery reviews.

[41]  Kenneth A. Dawson,et al.  Nanotoxicology: nanoparticles reconstruct lipids. , 2009, Nature nanotechnology.

[42]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[43]  Carmen Popescu,et al.  Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study , 2008, Pharmaceutical Research.

[44]  L. Mayer,et al.  Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes , 2008, Pharmaceutical Research.

[45]  Ben J Boyd,et al.  Past and future evolution in colloidal drug delivery systems , 2008, Expert opinion on drug delivery.

[46]  H. Shmeeda,et al.  An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin , 2008, Cancer Chemotherapy and Pharmacology.

[47]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[48]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[49]  David B Warheit,et al.  Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  Rebekah Drezek,et al.  Forming biocompatible and nonaggregated nanocrystals in water using amphiphilic polymers. , 2007, Journal of the American Chemical Society.

[51]  Jean-Pierre Benoit,et al.  Parameters influencing the stealthiness of colloidal drug delivery systems. , 2006, Biomaterials.

[52]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[53]  C. Benz,et al.  Future directions of liposome- and immunoliposome-based cancer therapeutics. , 2004, Seminars in oncology.

[54]  Cornelia M Keck,et al.  Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.

[55]  J. West,et al.  The Differential Cytotoxicity of Water-Soluble Fullerenes , 2004 .

[56]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[57]  Theresa M Allen,et al.  Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[58]  Sung-Wook Choi,et al.  Surface Modification of Functional Nanoparticles for Controlled Drug Delivery , 2003 .

[59]  R. Gurny,et al.  Biodegradable nanoparticles — From sustained release formulations to improved site specific drug delivery , 1996 .

[60]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[61]  R. Juliano,et al.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. , 1978, Biochemical pharmacology.

[62]  G. Birrenbach,et al.  Polymerized micelles and their use as adjuvants in immunology. , 1976, Journal of pharmaceutical sciences.

[63]  G Gregoriadis,et al.  Drug entrapment in liposomes , 1973, FEBS letters.

[64]  K. Shadan,et al.  Available online: , 2012 .